1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68:394–424.
2. Watanabe M, Tachimori Y, Oyama T, Toh Y, Matsubara H, Ueno M, et al. Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. Springer Singapore; 2021;18:1–24.
3. Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, et al. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. Journal of Surgical Oncology. 2015;112:597–602.
4. Kamarajah SK, Navidi M, Wahed S, Immanuel A, Hayes N, Griffin SM, et al. Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Annals of Surgical Oncology. Springer International Publishing; 2020;27:3182–92.
5. Bollschweiler E, Hölscher AH, Metzger R, Besch S, Mönig SP, Baldus SE, et al. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Annals of Thoracic Surgery. Elsevier Inc.; 2011;92:2020–7.
6. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. Journal of Clinical Oncology. 2005;23:4330–7.
7. Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery. 2007;141:570–80.
8. Hiraki Y, Kimura Y, Imano M, Kato H, Iwama M, Shiraishi O, et al. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma. Surgery Today. Springer Singapore; 2021;51:118–26.
9. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Annals of Surgical Oncology. 2012;19:68–74.
10. Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: Final analysis of randomized controlled phase III trial FFCD 9901. Journal of Clinical Oncology. 2014;32:2416–22.
11. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.
12. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 2. Esophagus. 2019;16:25–43.
13. Yamasaki M, Yasuda T, Yano M, Hirao M, Kobayashi K, Fujitani K, et al. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Annals of Oncology. Elsevier Masson SAS; 2017;28:116–20.
14. Hsu PK, Chien LI, Wang LC, Chou TY. Lymphovascular invasion and extracapsular invasion are risk factors for distant recurrence after preoperative chemoradiotherapy and oesophagectomy in patients with oesophageal squamous cell carcinoma. European Journal of Cardio-thoracic Surgery. 2017;51:1188–94.
15. Tu CC, Hsu PK, Chien LI, Liu WC, Huang CS, Hsieh CC, et al. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery. BMC Cancer. BMC Cancer; 2017;17:1–9.
16. Lagarde SM, Phillips AW, Navidi M, Disep B, Immanuel A, Griffin SM. The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. British Journal of Cancer. Nature Publishing Group; 2015;113:1427–33.
17. Lee PC, Mirza FM, Port JL, Stiles BM, Paul S, Christos P, et al. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. Journal of Thoracic and Cardiovascular Surgery. The American Association for Thoracic Surgery; 2011;141:1196–206.
18. Wang N, Jia Y, Wang J, Wang X, Bao C, Song Q, et al. Prognostic significance of lymph node ratio in esophageal cancer. Tumor Biology. 2015;36:2335–41.
19. Moon DH, Jeon JH, Yang HC, Kim Y Il, Lee JY, Kim MS, et al. Intramural Metastasis as a Risk Factor for Recurrence in Esophageal Squamous Cell Carcinoma. Annals of Thoracic Surgery. The Society of Thoracic Surgeons; 2018;106:249–56.
20. Khan M, Urooj N, Syed AA, Khattak S, Kazmi A, Ashraf MI, et al. Prognostic Factors for Recurrence in Esophageal Cancer Patients Treated With Neoadjuvant Therapy and Surgery: A Single-institution Analysis. Cureus. 2020;12.
21. Kang CH, Hwang Y, Lee HJ, Park IK, Kim YT. Risk Factors for Local Recurrence and Optimal Length of Esophagectomy in Esophageal Squamous Cell Carcinoma. Annals of Thoracic Surgery. The Society of Thoracic Surgeons; 2016;102:1074–80.
22. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus : official journal of the Japan Esophageal Society. NLM (Medline); 2017;14:1–36.
23. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus : official journal of the Japan Esophageal Society. 2017;14:37–65.
24. Markar SR, Gronnier C, Duhamel A, Pasquer A, Thereaux J, Du Rieu MC, et al. Significance of microscopically incomplete resection margin after esophagectomy for esophageal cancer. Annals of Surgery. 2016;263:712–8.
25. Hulshoff JB, Faiz Z, Karrenbeld A, Kats-Ugurlu G, Burgerhof JGM, Smit JK, et al. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology. 2015;22:1301–9.
26. Gilbert S, Martel AB, Seely AJ, Maziak DE, Shamji FM, Sundaresan SR, et al. Prognostic significance of a positive radial margin after esophageal cancer resection. Journal of Thoracic and Cardiovascular Surgery. Elsevier Inc.; 2015;149:548–55.
27. Jo Schlick CR, Khorfan R, Odell DD, Merkow RP, Bentrem DJ. Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors? Annals of Surgical Oncology [Internet]. 2020 [cited 2021 Aug 27];27:1496–507. Available from: https://doi.org/10.1245/s10434-019-08176-z
28. Yoshida N, Baba Y, Shigaki H, Harada K, Iwatsuki M, Sakamoto Y, et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma. International Journal of Clinical Oncology. Springer Japan; 2016;21:1071–8.
29. Zhang H, Chen X, Wang S, Fan J, Lu L. Poorer prognosis associated with simultaneous lymphatic and vascular invasion in patients with squamous carcinoma of the thoracic oesophagus. European Journal of Cardio-thoracic Surgery. 2017;52:378–84.
30. Inomata M, Shiroshita H, Uchida H, Bandoh T, Akira S, Yamaguchi S, et al. Current status of endoscopic surgery in Japan: The 14th National Survey of Endoscopic Surgery by the Japan Society for Endoscopic Surgery. Asian journal of endoscopic surgery. 2020;13:7–18.
31. Udagawa H. Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer. Annals of Gastroenterological Surgery. 2020;4:324–30.
32. Matsuda S, Takeuchi H, Kawakubo H, Kitagawa Y. Three-field lymph node dissection in esophageal cancer surgery. Journal of Thoracic Disease. 2017;9:S731–40.
33. Shang QX, Chen LQ, Hu WP, Deng HY, Yuan Y, Cai J. Three-field lymph node dissection in treating the esophageal cancer. Journal of Thoracic Disease. 2016;8:E1136–49.
34. Ye T, Sun Y, Zhang Y, Zhang Y, Chen H. Three-field or two-field resection for thoracic esophageal cancer: A meta-analysis. Annals of Thoracic Surgery. Elsevier Inc; 2013;96:1933–41.
35. Ma GW, Situ DR, Ma QL, Long H, Zhang LJ, Lin P, et al. Three-field vs two-field lymph node dissection for esophageal cancer: A meta-analysis. World Journal of Gastroenterology. 2014;20:18022–30.
36. Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Annals of Surgery. 2002;236:177–83.
37. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: Impact on staging, disease-free survival, and outcome: A plea for adaptation of TNM classification in upper-half esophageal carcinoma. Annals of Surgery. 2004;240:962–74.
38. Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O’Byrne K, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Annals of Surgery. 2007;245:707–16.
39. Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Annals of Surgery. 2008;247:365–71.
40. Talsma AK, Shapiro J, Looman CWN, Van Hagen P, Steyerberg EW, Van Der Gaast A, et al. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy : Prognostic and therapeutic impact on survival. Annals of Surgery. 2014;260:786–93.
41. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–55.
42. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Annals of Surgery. 2005;242:684–92.
43. Miyata H, Tanaka K, Makino T, Yamasaki M, Miyazaki Y, Takahashi T, et al. The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology. Springer International Publishing; 2018;25:2409–17.